ArticleAnnals of medicine and surgery (2012)2022
An otherwise healthy male developed COVID-19 disease after the use of anabolic steroid: The second case report.
Article in Annals of medicine and surgery (2012), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: COVID-19 disease is considered a highly risky pandemic which led to more victims during the last two years. Case presentation: We present a case of a 32 athlete male patient who presented with covid-19 symptoms. Past medical history was unremarkable except for oxandrolone (an anabolic steroid) 30/day for bodybuilding 21 days before the presentation. He reported that his symptoms developed rapidly in the past two days. After taking patient consent, we started the treatment with a single dose of anti-androgen (proxlatumide 400 mg) followed by 200 mg daily for one week. There was no need for hospital admission. On-call follow-up showed a marked response with resolving of most symptoms. Follow-up for six weeks later demonstrated a full recovery. Discussion: Using anabolic androgen steroids have been considered a risk factor for developing pneumonia. With the wide use between bodybuilders, many reports showed a link between the use of such drugs and COVID-19 disease. Anti-androgen drugs may lead to resolution of the symptoms. Conclusion: To the best of our knowledge, this is the second case reporting the link between anabolic steroids use and covid-19 disease severity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.